End-of-day quote
Bulgaria S.E.
23:00:00 28/04/2024 BST
|
5-day change
|
1st Jan Change
|
17.4
BGN
|
+0.58%
|
|
-.--%
|
+2.35%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
649.8
|
896
|
1,141
|
1,259
|
1,360
|
1,510
|
Enterprise Value (EV)
1 |
659.9
|
908
|
1,153
|
1,271
|
1,372
|
1,521
|
P/E ratio
|
54.8
x
|
273
x
|
3,381
x
|
746
x
|
469
x
|
444
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
17.1
x
|
25.5
x
|
28.5
x
|
29.7
x
|
31.7
x
|
31.1
x
|
EV / Revenue
|
17.3
x
|
25.9
x
|
28.8
x
|
30
x
|
31.9
x
|
31.3
x
|
EV / EBITDA
|
41.9
x
|
136
x
|
251
x
|
227
x
|
211
x
|
246
x
|
EV / FCF
|
-180
x
|
1,315
x
|
91.3
x
|
1,499
x
|
-1,770
x
|
-631
x
|
FCF Yield
|
-0.55%
|
0.08%
|
1.1%
|
0.07%
|
-0.06%
|
-0.16%
|
Price to Book
|
6.91
x
|
9.25
x
|
11.8
x
|
12.7
x
|
13.4
x
|
14.4
x
|
Nbr of stocks (in thousands)
|
88,800
|
88,800
|
88,800
|
88,800
|
88,800
|
88,800
|
Reference price
2 |
7.318
|
10.09
|
12.85
|
14.18
|
15.32
|
17.00
|
Announcement Date
|
28/03/19
|
30/01/20
|
01/03/21
|
28/02/22
|
28/02/23
|
10/04/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
38.06
|
35.07
|
40.03
|
42.43
|
42.96
|
48.51
|
EBITDA
1 |
15.74
|
6.694
|
4.588
|
5.591
|
6.501
|
6.182
|
EBIT
1 |
12.43
|
3.378
|
0.363
|
1.796
|
3.17
|
4.007
|
Operating Margin
|
32.65%
|
9.63%
|
0.91%
|
4.23%
|
7.38%
|
8.26%
|
Earnings before Tax (EBT)
1 |
12.42
|
3.059
|
0.554
|
1.899
|
3.251
|
3.868
|
Net income
1 |
11.2
|
2.845
|
0.344
|
1.667
|
2.901
|
3.398
|
Net margin
|
29.43%
|
8.11%
|
0.86%
|
3.93%
|
6.75%
|
7%
|
EPS
2 |
0.1334
|
0.0370
|
0.003800
|
0.0190
|
0.0327
|
0.0383
|
Free Cash Flow
1 |
-3.659
|
0.6905
|
12.62
|
0.848
|
-0.7751
|
-2.412
|
FCF margin
|
-9.61%
|
1.97%
|
31.53%
|
2%
|
-1.8%
|
-4.97%
|
FCF Conversion (EBITDA)
|
-
|
10.32%
|
275.14%
|
15.17%
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
24.27%
|
3,669.55%
|
50.87%
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
28/03/19
|
30/01/20
|
01/03/21
|
28/02/22
|
28/02/23
|
10/04/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
10.1
|
12
|
12
|
11.8
|
11.7
|
11.1
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
0.6432
x
|
1.789
x
|
2.613
x
|
2.116
x
|
1.794
x
|
1.796
x
|
Free Cash Flow
1 |
-3.66
|
0.69
|
12.6
|
0.85
|
-0.78
|
-2.41
|
ROE (net income / shareholders' equity)
|
12.7%
|
2.98%
|
0.36%
|
1.7%
|
2.89%
|
3.29%
|
ROA (Net income/ Total Assets)
|
7.47%
|
1.85%
|
0.19%
|
0.96%
|
1.67%
|
2.07%
|
Assets
1 |
150
|
153.4
|
177.9
|
173.6
|
173.6
|
164.4
|
Book Value Per Share
2 |
1.060
|
1.090
|
1.090
|
1.110
|
1.150
|
1.180
|
Cash Flow per Share
2 |
0
|
0
|
0
|
0
|
0
|
0
|
Capex
1 |
1.4
|
0.99
|
2.82
|
1.57
|
1.58
|
1.91
|
Capex / Sales
|
3.68%
|
2.82%
|
7.04%
|
3.71%
|
3.68%
|
3.94%
|
Announcement Date
|
28/03/19
|
30/01/20
|
01/03/21
|
28/02/22
|
28/02/23
|
10/04/24
|
|
1st Jan change
|
Capi.
|
---|
| +2.35% | 844M | | +20.61% | 43.18B | | +20.67% | 22.59B | | +14.56% | 14.56B | | +13.94% | 13.54B | | +43.35% | 11.5B | | -8.37% | 6.93B | | -0.05% | 6.79B | | -8.87% | 5.73B | | +10.21% | 5.36B |
Generic Pharmaceuticals
|